Syndax assumed with a Buy at Jefferies

Jefferies assumed coverage of Syndax (SNDX) with a Buy rating and a price target of $40, down from $48. Revuforj is winning today and the competition from Kura Oncology (KURA) looks “manageable,” says the analyst, who views as “a commercial execution story with layered upside.”